Clozapine: Does it work? Analysis of a 15 year experience
|
|
- Vivian Lambert
- 5 years ago
- Views:
Transcription
1 Article ID: WMC ISSN Clozapine: Does it work? Analysis of a 15 year experience Corresponding Author: Dr. Ennio Piantato, Division Chief / Dept of Mental Health, Azienda Ospedaliera Nazionale, Alessandria, Italy Submitting Author: Dr. Ennio Piantato, Division Chief / Dept of Mental Health, Azienda Ospedaliera Nazionale, Alessandria, Italy Article ID: WMC Article Type: Case Report Submitted on:24-sep-2011, 12:17:58 PM GMT Article URL: Subject Categories:PSYCHIATRY Keywords:Clozapine, Schizophrenia, Results Source(s) of Funding: No funding required Competing Interests: None WebmedCentral > Case Report Page 1 of 21
2 Clozapine: Does it work? Analysis of a 15 year experience Author(s): Piantato E, Sartore F Abstract Afterwards the treatment with Clozapine was extended to patients affected by non-schizophrenic disturbances such as bipolar disorder. MATERIAL AND METHODS Clozapine: does it work? Analysis of a 15 year experience. Ennio PIANTATO and Francesca SARTORE Our report includes the group of patients currently taking Clozapine and attending our centre for blood test control. Almost all of them started Clozapine while hospitalized in our Psychiatric Unit. At the moment the group is made up of 54 patients: 41 males (76%) and 13 females (24%). ABSTRACT This is an overview of results after a 15 year follow-up of psychotic patients treated mainly with Clozapine. We have found out that their quality of life has improved, they are good compliant in taking their medications and the number of hospitalizations is greatly reduced after beginning treatment with Clozapine. Originally the use of Clozapine began with 6 patients (4 males and 2 females) who are still under the care of our centre. Average age of patients is 43±9.9 for the total group: for the male group average age is 40, for the female group it is 46. Age range is from 26 to 69 years. INTRODUCTION This report contains data about use of Clozapine in our Psychiatric Unit during the period June 1995-June All patients live at home with 8 exceptions: 6 of them live in sheltered apartments and 1 is in a nursing home. Regarding the diagnoses, 48 patients (88.9%) are affected by schizophrenia, 4 (7.4%) by a schizoaffective disorder and 2 (3.7%) by bipolar disorder with psychotic behaviour. (Tab 1). Clozapine is an anti-psychotic drug created at the end of 60 s, with a particular receptor profile. Due to some cases of granulocytopenia noted in Finland the drug was withdrawn in It was reintroduced in the 90 s with indication for resistant schizophrenia and a recommendation to monitor blood cell counts. Since 1995 Clozapine has been officially used in Italy for resistant schizophrenia. In 1995 we started using Clozapine after two of us attended a course at the Psychiatric Clinic of the Bern University, Switzerland. Our Psychiatric Unit is part of a Department of Mental Health and situated in the Alessandria general hospital, in the region of Piedmont in NW Italy, serving a population of inhabitants. The unit has 15 beds plus 1 bed for Day Hospital service. Initially Clozapine was used with so-called treatment-resistant schizophrenic patients, showing resistance to traditional and at least two atypical antipsychotic treatments as reported in international guidelines. [1] Tab 1: Diagnosis (total group) Diagnosis TOTAL MEN WOMEN Schizophrenia Schizoaffective disorder Bipolar disorder Patients affected by schizophrenia are subdivided as follows: paranoid schizophrenia (19); undifferentiated disorder (12); disorganized schizophrenia (15); catatonic schizophrenia (1) chronic (1) (Tab 2) Tab 2 : Schizophrenia sub-types Sub-type TOTAL MEN WOMEN Catatonic Disorganized Undifferentiated Paranoid Chronic Our doses of Clozapine vary from 100 to 900 mg per day: doses are higher usually - on discharge from hospital (150 to 900 mg per day) WebmedCentral > Case Report Page 2 of 21
3 then they tend to diminish to a medium 75 to 600 mg per day. Clozapine is used as monotherapy in 19 patients (35.1%). It s also used in association with other psychotropic drugs (sometimes more than one per category) in remaining cases: more precisely in association with mood-stabilizers in 19 patients, antisialorroic drugs in 4 patients, anticholinergic medications in 19 patients, other antipsychotic drugs in 20 patients, benzodiazepines in 10 patients and antidepressants in 3 patients. Regarding the association between Clozapine and other antipsychotics we found that two patients of the group have been included in the CHAT study (experimental cohort with Clozapine enhanced associating another antipsychotic drug, aripiprazole or haloperidol). [6] No patient of ours has tried or succeeded in committing suicide so far and this is consistent with other reports [7]. Clozapine has also produced good results with patients whose behaviour had been violent specially in a etero-directed way. We have observed that the side effects of treatment with Clozapine are most frequently:- sialorrea (excessive salivation); constipation; low blood pressure; psychomotor slowing; weight increase; in one case an epileptic fit was controlled by adding an anti-epileptic drug so the global treatment could be continued without having any other problem; two patients are affected by epilepsy in co-morbidity and take anti-epileptic drugs. In this group we have not had any granulocytopenia. We have observed a reduction in hospital admissions after beginning treatment with Clozapine, above all in the male group. In 22 patients (40.7% of the group) we haven t had further hospital admissions. (Tab 3 and 4). Tab 3 : Hospitalizations TOTAL MEN WOMEN Total number of hospitalizations Before treatment with clozapine After treatment with clozapine Scientific evidence shows that continuous use of anti-psychotic drugs in schizophrenics prevents relapses. Compliance with treatment is important in all chronic pathologies and in our group especially an interruption of treatment provokes various consequences, first of all the risk of a relapse with hospitalization (up to revolving-door conditions) plus blockage of the personal therapeutic and rehabilitation project. The reduction in hospitalization observed in our group is the verification of good compliance with treatment included the regular carrying out of their blood tests. Moreover patients have been also monitored via analysis of plasma levels of Clozapine. We have begun to use metformin in some of our patients to control weight gain due to the treatment with Clozapine: so far the results appear good but the time of observation (4 months) is too short to allow us to be more specific. [8,9] CONCLUSION Tab 4 : Patients never re-hospitalized after treatment with Clozapine TOTAL 22 (41.7%) MEN 15 WOMEN 7 DISCUSSION Results The reduction of hospitalizations is reported [2,3] and explained as effect of objective improvement of some clinical parameters and better social and job adaptability [4] this is consistent with the self evaluated subjective improvement registered by our patients and by authors. [5] Clozapine alone isn t always enough. In our group Clozapine is often associated with other psychotropic drugs and it is used as the only antipsychotic drug in 19 patients; among most frequently used drugs in association there are other first and second generation antipsychotics. Clozapine is an antipsychotic whose use is limited by some side effects, some of which are potentially deadly. Many clinical studies have confirmed its efficacy especially on positive schizophrenic symptoms in the long term treatment and in drug-resistant schizophrenia, moreover it is the antipsychotic used in case of psychoses in patients with Parkinson s disease. [10,11,12,13] Our considerations, based on our clinical group, are in line with results of these studies: this is particularly evident in patients who have never been re-hospitalized after taking Clozapine notwithstanding the gravity of their mental pathology: i.e. two women had even previously been treated with convulsive therapy, so far both of them have had good health since 1995 after since using Clozapine. REFERENCES 1. Società Italiana di Psicopatologia, Consensus Conference: Linee guida per la Farmacoterapia della schizofrenia, Roma, aprile 2000 WebmedCentral > Case Report Page 3 of 21
4 2.Breier A, Buchanan RW, Irish D, Carpenter WT Jr.: Clozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns. Hosp Community Psychiatry 1993; 44: 12: Meltzer HY, Burnett S, Bastani B, Ramirez LF.: Effects of Six Months of Clozapine Treatment on the Quality of Life of Chronic Schizophrenic Patients. Hosp Community Psychiatry 1990; 41: Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz Beth: Cost Effectiveness of Clozapine in Neuroleptic-Resistant Schizophrenia. Am J Psychiatry 1993; 150: prescription de la clozapine au centre hospitalier Charles-Perrens à Bordeaux, plus de 15 ans après l AMM en France. L Encéphale. 2009; XXXV (4): Waserman J, Criollo: M. Subjective Experience of Clozapine Treatment by Patients With Chronic Schizophrenia. Psychiatric Services 2000; 51: 5: Nosè M, Accordini S, Artioli P, Barale F, Barbui C. et Alii: Rationale and Design of an Independent Randomised Controlled Trial Evaluating the Effectiveness of Aripiprazole or Haloperidol in Combination with Clozapine for Treatment-Resistant Schizophrenia. Trials May 15; Llorca PM, Perez JJ.: Leponex, 10 ans après. Une revue clinique. L Encéphale, 2004; XXX: Schumann SA, Ewigman B.: Can Metformin Undo Weight Gain Induced by Antipsychotics? J Fam Pract Aug; 57 (8): Ness-Abramof R, Apovian CM.: Drug-induced Weight Gain. Drugs Today Aug; 41 (8): Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr.: Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without Deficit Syndrome. Am J Psychiatry 1998; 155: 6: Leiderman EA.: Effectiveness Trials in Chronic Schizophrenic Patients: CATIE. What can we learn? Vertex 2009; 20;(84); Essali A, Al-Haj Haasan N, Li C, Rathbone J.: Clozapine vs Typical Neuroleptic Medication for Schizophrenia. Cochrane Database Syst Rev. 2009; Jan 21; (1): CD Mercier C, Bret P, Bret MC, Queuille E.: Enquête observationelle de Ennio Piantato MD, Servizio Psichiatrico Azienda Ospedaliera Nazionale SS Antonio e Biagio, via Venezia Alessandria Italy Tel Fax WebmedCentral > Case Report Page 4 of 21
5 Both Authors equally contributed to this article. Francesca Sartore MD Servizio Psichiatrico Azienda Ospedaliera Nazionale SS Antonio e Biagio Via Venezia Alessandria Italy Tel Fax Clozapine: does it work? Analysis of a 15 year experience. Ennio PIANTATO and Francesca SARTORE ABSTRACT This is an overview of results after a 15 year follow-up of psychotic patients treated mainly with Clozapine. We have found out that their quality of life has improved, they are good compliant in taking their medications and the number of hospitalizations is greatly reduced after beginning treatment with Clozapine. > fsartore@ospedale.al.it INTRODUCTION This report contains data about use of Clozapine in our Psychiatric Unit during the period June 1995-June WebmedCentral > Case Report Page 5 of 21
6 Age range is from 26 to 69 years. Clozapine is an anti-psychotic drug created at the end of 60 s, with a particular receptor profile. Due to some cases of granulocytopenia noted in Finland the drug was withdrawn in It was reintroduced in the 90 s with indication for resistant schizophrenia and a recommendation to monitor blood cell counts. Since 1995 Clozapine has been officially used in Italy for resistant schizophrenia. In 1995 we started using Clozapine after two of us attended a course at the Psychiatric Clinic of the Bern University, Switzerland. Our Psychiatric Unit is part of a Department of Mental Health and situated in the Alessandria general hospital, in the region of Piedmont in NW Italy, serving a population of inhabitants. The unit has 15 beds plus 1 bed for Day Hospital service. Initially Clozapine was used with so-called treatment-resistant schizophrenic patients, showing resistance to traditional and at least two atypical antipsychotic treatments as reported in international guidelines. [1] Afterwards the treatment with Clozapine was extended to patients affected by non-schizophrenic disturbances such as bipolar disorder. MATERIAL AND METHODS Our report includes the group of patients currently taking Clozapine and attending our centre for blood test control. Almost all of them started Clozapine while hospitalized in our Psychiatric Unit. At the moment the group is made up of 54 patients: 41 males (76%) and 13 females (24%). Originally the use of Clozapine began with 6 patients (4 males and 2 females) who are still under the care of our centre. Average age of patients is 43±9.9 for the total group: for the male group average age is 40, for the female group it is 46. All patients live at home with 8 exceptions: 6 of them live in sheltered apartments and 1 is in a nursing home. Regarding the diagnoses, 48 patients (88.9%) are affected by schizophrenia, 4 (7.4%) by a schizoaffective disorder and 2 (3.7%) by bipolar disorder with psychotic behaviour. (Tab 1). Tab 1: Diagnosis (total group) Diagnosis TOTAL MEN WOMEN Schizophrenia Schizoaffective disorder Bipolar disorder Patients affected by schizophrenia are subdivided as follows: paranoid schizophrenia (19); undifferentiated disorder (12); disorganized schizophrenia (15); catatonic schizophrenia (1) chronic (1) (Tab 2) Tab 2 : Schizophrenia sub-types Sub-type TOTAL MEN WOMEN Catatonic Disorganized Undifferentiated Paranoid Chronic Our doses of Clozapine vary from 100 to 900 mg per day: doses are higher usually - on discharge from hospital (150 to 900 mg per day) then they tend to diminish to a medium 75 to 600 mg per day. Clozapine is used as monotherapy in 19 patients (35.1%). It s also used in association with other psychotropic drugs (sometimes more than one per category) in remaining cases: more precisely in association with mood-stabilizers in 19 patients, antisialorroic drugs in 4 patients, anticholinergic medications in 19 patients, other antipsychotic drugs in 20 patients, benzodiazepines in 10 patients and antidepressants in 3 patients. We have observed that the side effects of treatment with Clozapine are most frequently:- sialorrea (excessive salivation); constipation; low blood pressure; psychomotor slowing; weight increase; WebmedCentral > Case Report Page 6 of 21
7 in one case an epileptic fit was controlled by adding an anti-epileptic drug so the global treatment could be continued without having any other problem; two patients are affected by epilepsy in co-morbidity and take anti-epileptic drugs. In this group we have not had any granulocytopenia. We have observed a reduction in hospital admissions after beginning treatment with Clozapine, above all in the male group. In 22 patients (40.7% of the group) we haven t had further hospital admissions. (Tab 3 and 4). Tab 3 : Hospitalizations TOTAL MEN WOMEN Total number of hospitalizations Before treatment with clozapine After treatment with clozapine Tab 4 : Patients never re-hospitalized after treatment with Clozapine TOTAL 22 (41.7%) MEN 15 WOMEN 7 No patient of ours has tried or succeeded in committing suicide so far and this is consistent with other reports [7]. Clozapine has also produced good results with patients whose behaviour had been violent specially in a etero-directed way. Scientific evidence shows that continuous use of anti-psychotic drugs in schizophrenics prevents relapses. Compliance with treatment is important in all chronic pathologies and in our group especially an interruption of treatment provokes various consequences, first of all the risk of a relapse with hospitalization (up to revolving-door conditions) plus blockage of the personal therapeutic and rehabilitation project. The reduction in hospitalization observed in our group is the verification of good compliance with treatment included the regular carrying out of their blood tests. Moreover patients have been also monitored via analysis of plasma levels of Clozapine. DISCUSSION Results The reduction of hospitalizations is reported [2,3] and explained as effect of objective improvement of some clinical parameters and better social and job adaptability [4] this is consistent with the self evaluated subjective improvement registered by our patients and by authors. [5] Clozapine alone isn t always enough. In our group Clozapine is often associated with other psychotropic drugs and it is used as the only antipsychotic drug in 19 patients; among most frequently used drugs in association there are other first and second generation antipsychotics. Regarding the association between Clozapine and other antipsychotics we found that two patients of the group have been included in the CHAT study (experimental cohort with Clozapine enhanced associating another antipsychotic drug, aripiprazole or haloperidol). [6] We have begun to use metformin in some of our patients to control weight gain due to the treatment with Clozapine: so far the results appear good but the time of observation (4 months) is too short to allow us to be more specific. [8,9] CONCLUSION Clozapine is an antipsychotic whose use is limited by some side effects, some of which are potentially deadly. Many clinical studies have confirmed its efficacy especially on positive schizophrenic symptoms in the long term treatment and in drug-resistant schizophrenia, moreover it is the antipsychotic used in case of psychoses in patients with Parkinson s disease. [10,11,12,13] Our considerations, based on our clinical group, are in line with results of these studies: this is particularly evident in patients who have never been re-hospitalized after taking Clozapine notwithstanding the gravity of their mental pathology: i.e. two women WebmedCentral > Case Report Page 7 of 21
8 had even previously been treated with convulsive therapy, so far both of them have had good health since 1995 after since using Clozapine. REFERENCES 1. Società Italiana di Psicopatologia, Consensus Conference: Linee guida per la Farmacoterapia della schizofrenia, Roma, aprile Breier A, Buchanan RW, Irish D, Carpenter WT Jr.: Clozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns. Hosp Community Psychiatry 1993; 44: 12: Meltzer HY, Burnett S, Bastani B, Ramirez LF.: Effects of Six Months of Clozapine Treatment on the Quality of Life of Chronic Schizophrenic Patients. Hosp Community Psychiatry 1990; 41: Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz Beth: Cost Effectiveness of Clozapine in Neuroleptic-Resistant Schizophrenia. Am J Psychiatry 1993; 150: Waserman J, Criollo: M. Subjective Experience of Clozapine Treatment by Patients With Chronic Schizophrenia. Psychiatric Services 2000; 51: 5: Nosè M, Accordini S, Artioli P, Barale F, Barbui C. et Alii: Rationale and Design of an Independent Randomised Controlled Trial Evaluating the Effectiveness of Aripiprazole or Haloperidol in Combination with Clozapine for Treatment-Resistant Schizophrenia. Trials May 15; Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr.: Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without Deficit Syndrome. Am J Psychiatry 1998; 155: 6: Leiderman EA.: Effectiveness Trials in Chronic Schizophrenic Patients: CATIE. What can we learn? Vertex 2009; 20;(84); Essali A, Al-Haj Haasan N, Li C, Rathbone J.: Clozapine vs Typical Neuroleptic Medication for Schizophrenia. Cochrane Database Syst Rev. 2009; Jan 21; (1): CD Mercier C, Bret P, Bret MC, Queuille E.: Enquête observationelle de prescription de la clozapine au centre hospitalier Charles-Perrens à Bordeaux, plus de 15 ans après l AMM en France. L Encéphale. 2009; XXXV (4): Llorca PM, Perez JJ.: Leponex, 10 ans après. Une revue clinique. L Encéphale, 2004; XXX: Schumann SA, Ewigman B.: Can Metformin Undo Weight Gain Induced by Antipsychotics? J Fam Pract Aug; 57 (8): Ness-Abramof R, Apovian CM.: Drug-induced Weight Gain. Drugs Today Aug; 41 (8): Ennio Piantato MD, Servizio Psichiatrico WebmedCentral > Case Report Page 8 of 21
9 Azienda Ospedaliera Nazionale SS Antonio e Biagio, via Venezia Alessandria Italy Tel Fax Via Venezia Alessandria Italy Tel Fax > fsartore@ospedale.al.it epiantato@ospedale.al.it Francesca Sartore MD Both Authors equally contributed to this article. Servizio Psichiatrico Azienda Ospedaliera Nazionale SS Antonio e Biagio WebmedCentral > Case Report Page 9 of 21
10 Clozapine: does it work? Analysis of a 15 year experience. Ennio PIANTATO and Francesca SARTORE Initially Clozapine was used with so-called treatment-resistant schizophrenic patients, showing resistance to traditional and at least two atypical antipsychotic treatments as reported in international guidelines. [1] Afterwards the treatment with Clozapine was extended to patients affected by non-schizophrenic disturbances such as bipolar disorder. MATERIAL AND METHODS ABSTRACT This is an overview of results after a 15 year follow-up of psychotic patients treated mainly with Clozapine. We have found out that their quality of life has improved, they are good compliant in taking their medications and the number of hospitalizations is greatly reduced after beginning treatment with Clozapine. INTRODUCTION This report contains data about use of Clozapine in our Psychiatric Unit during the period June 1995-June Clozapine is an anti-psychotic drug created at the end of 60 s, with a particular receptor profile. Due to some cases of granulocytopenia noted in Finland the drug was withdrawn in It was reintroduced in the 90 s with indication for resistant schizophrenia and a recommendation to monitor blood cell counts. Since 1995 Clozapine has been officially used in Italy for resistant schizophrenia. Our report includes the group of patients currently taking Clozapine and attending our centre for blood test control. Almost all of them started Clozapine while hospitalized in our Psychiatric Unit. At the moment the group is made up of 54 patients: 41 males (76%) and 13 females (24%). Originally the use of Clozapine began with 6 patients (4 males and 2 females) who are still under the care of our centre. Average age of patients is 43±9.9 for the total group: for the male group average age is 40, for the female group it is 46. Age range is from 26 to 69 years. All patients live at home with 8 exceptions: 6 of them live in sheltered apartments and 1 is in a nursing home. Regarding the diagnoses, 48 patients (88.9%) are affected by schizophrenia, 4 (7.4%) by a schizoaffective disorder and 2 (3.7%) by bipolar disorder with psychotic behaviour. (Tab 1). In 1995 we started using Clozapine after two of us attended a course at the Psychiatric Clinic of the Bern University, Switzerland. Our Psychiatric Unit is part of a Department of Mental Health and situated in the Alessandria general hospital, in the region of Piedmont in NW Italy, serving a population of inhabitants. The unit has 15 beds plus 1 bed for Day Hospital service. Tab 1: Diagnosis (total group) Diagnosis TOTAL MEN WOMEN Schizophrenia Schizoaffective disorder Bipolar disorder Patients affected by schizophrenia are subdivided as follows: paranoid schizophrenia (19); undifferentiated disorder (12); disorganized schizophrenia (15); catatonic schizophrenia (1) chronic (1) (Tab 2) WebmedCentral > Case Report Page 10 of 21
11 Tab 2 : Schizophrenia sub-types Sub-type TOTAL MEN WOMEN Catatonic Disorganized Undifferentiated Paranoid Chronic TOTAL 22 (41.7%) MEN 15 WOMEN 7 DISCUSSION Results Our doses of Clozapine vary from 100 to 900 mg per day: doses are higher usually - on discharge from hospital (150 to 900 mg per day) then they tend to diminish to a medium 75 to 600 mg per day. Clozapine is used as monotherapy in 19 patients (35.1%). It s also used in association with other psychotropic drugs (sometimes more than one per category) in remaining cases: more precisely in association with mood-stabilizers in 19 patients, antisialorroic drugs in 4 patients, anticholinergic medications in 19 patients, other antipsychotic drugs in 20 patients, benzodiazepines in 10 patients and antidepressants in 3 patients. We have observed that the side effects of treatment with Clozapine are most frequently:- sialorrea (excessive salivation); constipation; low blood pressure; psychomotor slowing; weight increase; in one case an epileptic fit was controlled by adding an anti-epileptic drug so the global treatment could be continued without having any other problem; two patients are affected by epilepsy in co-morbidity and take anti-epileptic drugs. In this group we have not had any granulocytopenia. We have observed a reduction in hospital admissions after beginning treatment with Clozapine, above all in the male group. In 22 patients (40.7% of the group) we haven t had further hospital admissions. (Tab 3 and 4). Tab 3 : Hospitalizations TOTAL MEN WOMEN Total number of hospitalizations Before treatment with clozapine After treatment with clozapine Tab 4 : Patients never re-hospitalized after treatment with Clozapine The reduction of hospitalizations is reported [2,3] and explained as effect of objective improvement of some clinical parameters and better social and job adaptability [4] this is consistent with the self evaluated subjective improvement registered by our patients and by authors. [5] Clozapine alone isn t always enough. In our group Clozapine is often associated with other psychotropic drugs and it is used as the only antipsychotic drug in 19 patients; among most frequently used drugs in association there are other first and second generation antipsychotics. Regarding the association between Clozapine and other antipsychotics we found that two patients of the group have been included in the CHAT study (experimental cohort with Clozapine enhanced associating another antipsychotic drug, aripiprazole or haloperidol). [6] No patient of ours has tried or succeeded in committing suicide so far and this is consistent with other reports [7]. Clozapine has also produced good results with patients whose behaviour had been violent specially in a etero-directed way. Scientific evidence shows that continuous use of anti-psychotic drugs in schizophrenics prevents relapses. Compliance with treatment is important in all chronic pathologies and in our group especially an interruption of treatment provokes various consequences, first of all the risk of a relapse with hospitalization (up to revolving-door conditions) plus blockage of the personal therapeutic and rehabilitation project. The reduction in hospitalization observed in our group is the verification of good compliance with treatment WebmedCentral > Case Report Page 11 of 21
12 included the regular carrying out of their blood tests. Moreover patients have been also monitored via analysis of plasma levels of Clozapine. We have begun to use metformin in some of our patients to control weight gain due to the treatment with Clozapine: so far the results appear good but the time of observation (4 months) is too short to allow us to be more specific. [8,9] CONCLUSION Clozapine is an antipsychotic whose use is limited by some side effects, some of which are potentially deadly. Many clinical studies have confirmed its efficacy especially on positive schizophrenic symptoms in the long term treatment and in drug-resistant schizophrenia, moreover it is the antipsychotic used in case of psychoses in patients with Parkinson s disease. [10,11,12,13] Our considerations, based on our clinical group, are in line with results of these studies: this is particularly evident in patients who have never been re-hospitalized after taking Clozapine notwithstanding the gravity of their mental pathology: i.e. two women had even previously been treated with convulsive therapy, so far both of them have had good health since 1995 after since using Clozapine. REFERENCES 1. Società Italiana di Psicopatologia, Consensus Conference: Linee guida per la Farmacoterapia della schizofrenia, Roma, aprile Breier A, Buchanan RW, Irish D, Carpenter WT Jr.: Clozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns. Hosp Community Psychiatry 1993; 44: 12: Meltzer HY, Burnett S, Bastani B, Ramirez LF.: Effects of Six Months of Clozapine Treatment on the Quality of Life of Chronic Schizophrenic Patients. Hosp Community Psychiatry 1990; 41: Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz Beth: Cost Effectiveness of Clozapine in Neuroleptic-Resistant Schizophrenia. Am J Psychiatry 1993; 150: Waserman J, Criollo: M. Subjective Experience of Clozapine Treatment by Patients With Chronic Schizophrenia. Psychiatric Services 2000; 51: 5: Nosè M, Accordini S, Artioli P, Barale F, Barbui C. et Alii: Rationale and Design of an Independent Randomised Controlled Trial Evaluating the Effectiveness of Aripiprazole or Haloperidol in Combination with Clozapine for Treatment-Resistant Schizophrenia. Trials May 15; Llorca PM, Perez JJ.: Leponex, 10 ans après. Une revue clinique. L Encéphale, 2004; XXX: Schumann SA, Ewigman B.: Can Metformin Undo Weight Gain Induced by Antipsychotics? J Fam Pract Aug; 57 (8): Ness-Abramof R, Apovian CM.: Drug-induced Weight Gain. Drugs Today Aug; 41 (8): Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr.: Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without Deficit Syndrome. Am J Psychiatry 1998; 155: 6: Leiderman EA.: Effectiveness Trials in Chronic Schizophrenic Patients: CATIE. What can we learn? Vertex 2009; 20;(84); Essali A, Al-Haj Haasan N, Li C, Rathbone J.: Clozapine vs Typical Neuroleptic Medication for Schizophrenia. Cochrane Database Syst Rev. 2009; Jan 21; (1): CD Mercier C, Bret P, Bret MC, Queuille E.: WebmedCentral > Case Report Page 12 of 21
13 Enquête observationelle de prescription de la clozapine au centre hospitalier Charles-Perrens à Bordeaux, plus de 15 ans après l AMM en France. L Encéphale. 2009; XXXV (4): Fax epiantato@ospedale.al.it Francesca Sartore MD Servizio Psichiatrico Ennio Piantato MD, Servizio Psichiatrico Azienda Ospedaliera Nazionale SS Antonio e Biagio, via Venezia Alessandria Italy Tel Azienda Ospedaliera Nazionale SS Antonio e Biagio Via Venezia Alessandria Italy Tel Fax WebmedCentral > Case Report Page 13 of 21
14 > Both Authors equally contributed to this article. reintroduced in the 90 s with indication for resistant schizophrenia and a recommendation to monitor blood cell counts. Since 1995 Clozapine has been officially used in Italy for resistant schizophrenia. In 1995 we started using Clozapine after two of us attended a course at the Psychiatric Clinic of the Bern University, Switzerland. Our Psychiatric Unit is part of a Department of Mental Health and situated in the Alessandria general hospital, in the region of Piedmont in NW Italy, serving a population of inhabitants. The unit has 15 beds plus 1 bed for Day Hospital service. Initially Clozapine was used with so-called treatment-resistant schizophrenic patients, showing resistance to traditional and at least two atypical antipsychotic treatments as reported in international guidelines. [1] Afterwards the treatment with Clozapine was extended to patients affected by non-schizophrenic disturbances such as bipolar disorder. Materials and Methods Our report includes the group of patients currently taking Clozapine and attending our centre for blood test control. Almost all of them started Clozapine while hospitalized in our Psychiatric Unit. At the moment the group is made up of 54 patients: 41 males (76%) and 13 females (24%). Originally the use of Clozapine began with 6 patients (4 males and 2 females) who are still under the care of our centre. This is an overview of results after a 15 year follow-up of psychotic patients treated mainly with Clozapine. We have found out that their quality of life has improved, they are good compliant in taking their medications and the number of hospitalizations is greatly reduced after beginning treatment with Clozapine. Introduction This report contains data about use of Clozapine in our Psychiatric Unit during the period June 1995-June Clozapine is an anti-psychotic drug created at the end of 60 s, with a particular receptor profile. Due to some cases of granulocytopenia noted in Finland the drug was withdrawn in It was Average age of patients is 43±9.9 for the total group: for the male group average age is 40, for the female group it is 46. Age range is from 26 to 69 years. All patients live at home with 8 exceptions: 6 of them live in sheltered apartments and 1 is in a nursing home. Regarding the diagnoses, 48 patients (88.9%) are affected by schizophrenia, 4 (7.4%) by a schizoaffective disorder and 2 (3.7%) by bipolar disorder with psychotic behaviour. (Tab 1). Our doses of Clozapine vary from 100 to 900 mg per day: doses are higher usually - on discharge from hospital (150 to 900 mg per day) then they tend to diminish to a medium 75 to 600 mg per day. Clozapine is used as monotherapy in 19 patients (35.1%). It s also used in association with other psychotropic drugs (sometimes more than one per category) in remaining cases: more precisely in association with mood-stabilizers in 19 patients, WebmedCentral > Case Report Page 14 of 21
15 antisialorroic drugs in 4 patients, anticholinergic medications in 19 patients, other antipsychotic drugs in 20 patients, benzodiazepines in 10 patients and antidepressants in 3 patients. We have observed that the side effects of treatment with Clozapine are most frequently:- sialorrea (excessive salivation); constipation; low blood pressure; psychomotor slowing; weight increase; in one case an epileptic fit was controlled by adding an anti-epileptic drug so the global treatment could be continued without having any other problem; two patients are affected by epilepsy in co-morbidity and take anti-epileptic drugs. In this group we have not had any granulocytopenia. We have observed a reduction in hospital admissions after beginning treatment with Clozapine, above all in the male group. In 22 patients (40.7% of the group) we haven t had further hospital admissions. (Tab 3 and 4). Discussion Results The reduction of hospitalizations is reported [2,3] and explained as effect of objective improvement of some clinical parameters and better social and job adaptability [4] this is consistent with the self evaluated subjective improvement registered by our patients and by authors. [5] Clozapine alone isn t always enough. In our group Clozapine is often associated with other psychotropic drugs and it is used as the only antipsychotic drug in 19 patients; among most frequently used drugs in association there are other first and second generation antipsychotics. Regarding the association between Clozapine and other antipsychotics we found that two patients of the group have been included in the CHAT study (experimental cohort with Clozapine enhanced associating another antipsychotic drug, aripiprazole or haloperidol). [6] No patient of ours has tried or succeeded in committing suicide so far and this is consistent with other reports [7]. Clozapine has also produced good results with patients whose behaviour had been violent specially in a etero-directed way. Scientific evidence shows that continuous use of anti-psychotic drugs in schizophrenics prevents relapses. Compliance with treatment is important in all chronic pathologies and in our group especially an interruption of treatment provokes various consequences, first of all the risk of a relapse with hospitalization (up to revolving-door conditions) plus blockage of the personal therapeutic and rehabilitation project. The reduction in hospitalization observed in our group is the verification of good compliance with treatment included the regular carrying out of their blood tests. Moreover patients have been also monitored via analysis of plasma levels of Clozapine. We have begun to use metformin in some of our patients to control weight gain due to the treatment with Clozapine: so far the results appear good but the time of observation (4 months) is too short to allow us to be more specific. [8,9] Conclusion Clozapine is an antipsychotic whose use is limited by some side effects, some of which are potentially deadly. Many clinical studies have confirmed its efficacy especially on positive schizophrenic symptoms in the long term treatment and in drug-resistant schizophrenia, moreover it is the antipsychotic used in case of psychoses in patients with Parkinson s disease. [10,11,12,13] Our considerations, based on our clinical group, are in line with results of these studies: this is particularly evident in patients who have never been re-hospitalized after taking Clozapine notwithstanding the gravity of their mental pathology: i.e. two women had even previously been treated with convulsive therapy, so far both of them have had good health since 1995 after since using Clozapine. References 1.Società Italiana di Psicopatologia, Consensus Conference: Linee guida per la Farmacoterapiadella schizofrenia, Roma, aprile Breier A, Buchanan RW, Irish D, Carpenter WT Jr.: Clozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns. Hosp Community Psychiatry 1993; 44: 12: Meltzer HY, Burnett S, Bastani B, Ramirez LF.: Effects of Six Months of Clozapine Treatment on the Quality of Life of Chronic Schizophrenic Patients. Hosp Community Psychiatry 1990; 41: Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz Beth: WebmedCentral > Case Report Page 15 of 21
16 Cost Effectiveness of Clozapine in Neuroleptic-Resistant Schizophrenia. Am J Psychiatry 1993; 150: Waserman J, Criollo: M. Subjective Experience of Clozapine Treatment by Patients With Chronic Schizophrenia. Psychiatric Services 2000; 51: 5: Nosè M, Accordini S, Artioli P, Barale F, Barbui C. et Alii: Rationale and Design of an Independent Randomised Controlled Trial Evaluating the Effectiveness of Aripiprazole or Haloperidol in Combination with Clozapine for Treatment-Resistant Schizophrenia. Trials May 15; Llorca PM, Perez JJ.: Leponex, 10 ans après. Une revue clinique. L Encéphale, 2004; XXX: Schumann SA, Ewigman B.: Can Metformin Undo Weight Gain Induced by Antipsychotics? J Fam Pract Aug; 57 (8): Ness-Abramof R, Apovian CM.: Drug-induced Weight Gain. Drugs Today Aug; 41 (8): Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr.: Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without Deficit Syndrome. Am J Psychiatry 1998; 155: 6: Leiderman EA.: Effectiveness Trials in Chronic Schizophrenic Patients: CATIE. What can we learn? Vertex 2009; 20;(84); Essali A, Al-Haj Haasan N, Li C, Rathbone J.: Clozapine vs Typical Neuroleptic Medication for Schizophrenia. Cochrane Database Syst Rev. 2009; Jan 21; (1): CD Mercier C, Bret P, Bret MC, Queuille E.: Enquête observationelle de prescription de la clozapine au centre hospitalier Charles-Perrens à Bordeaux, plus de 15 ans après l AMM en France. L Encéphale. 2009; XXXV (4): WebmedCentral > Case Report Page 16 of 21
17 Illustrations Illustration 1 Tab 1: Diagnosis (total group) Diagnosis TOTAL MEN WOMEN Schizophrenia Schizoaffective disorder Bipolar disorder Patients affected by schizophrenia are subdivided as follows: paranoid schizophrenia (19); undifferentiated disorder (12); disorganized schizophrenia (15); catatonic schizophrenia (1) chronic (1) (Tab 2) WebmedCentral > Case Report Page 17 of 21
18 Illustration 2 Tab 2 : Schizophrenia sub-types Sub-type TOTAL MEN WOMEN Catatonic Disorganized Undifferentiated Paranoid Chronic WebmedCentral > Case Report Page 18 of 21
19 Illustration 3 Tab 3 : Hospitalizations Total number of hospitalizations Before treatment with clozapine After treatment with clozapine TOTAL MEN WOMEN WebmedCentral > Case Report Page 19 of 21
20 Illustration 4 Tab 4 : Patients never re-hospitalized after treatment with Clozapine TOTAL 22 (41.7%) MEN 15 WOMEN 7 WebmedCentral > Case Report Page 20 of 21
21 Disclaimer This article has been downloaded from WebmedCentral. With our unique author driven post publication peer review, contents posted on this web portal do not undergo any prepublication peer or editorial review. It is completely the responsibility of the authors to ensure not only scientific and ethical standards of the manuscript but also its grammatical accuracy. Authors must ensure that they obtain all the necessary permissions before submitting any information that requires obtaining a consent or approval from a third party. Authors should also ensure not to submit any information which they do not have the copyright of or of which they have transferred the copyrights to a third party. Contents on WebmedCentral are purely for biomedical researchers and scientists. They are not meant to cater to the needs of an individual patient. The web portal or any content(s) therein is neither designed to support, nor replace, the relationship that exists between a patient/site visitor and his/her physician. Your use of the WebmedCentral site and its contents is entirely at your own risk. We do not take any responsibility for any harm that you may suffer or inflict on a third person by following the contents of this website. WebmedCentral > Case Report Page 21 of 21
Risk Factors Predicting Mortality in Spinal Cord Injury in Nigeria
Article ID: WMC00807 ISSN 2046690 Risk Factors Predicting Mortality in Spinal Cord Injury in Nigeria Corresponding Author: Dr. Ahidjo Kawu, Consultant Surgeon, Dept of Orthopaedics, UATH, Gwagwalada Abuja
More informationSupracondylar Process Congenitalis Of The Femur
Article ID: WMC00544 ISSN 2046-1690 Supracondylar Process Congenitalis Of The Femur Author(s):Dr. S S Suresh Corresponding Author: Dr. S S Suresh, Head of Department, IBRI Regional Referral Hospital, Department
More informationSignet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report
Article ID: WMC00688 ISSN 2046-1690 Signet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report Author(s):Dr. Pallavi Bhuyan, Dr. Smita Mahapatra, Dr. Sujata Pujari, Dr. Jayasree Rath
More informationArticle ID: WMC00791 ISSN
Article ID: WMC00791 ISSN 2046-1690 Shoe-smell Application as a First-aid Interventional Measure in Controlling Epileptic Attacks in an Urban Population in India: A Fortuitous Empirical Finding Author(s):Dr.
More informationBaseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston
Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,
More informationMore HIV Infection Among Housewvies Than Sex Workers In Malaysia
Article ID: WMC001557 ISSN 2046-1690 More HIV Infection Among Housewvies Than Sex Workers In Malaysia Corresponding Author: Mr. Mohamed Najimudeen, Associate Professor, Obstetrics and Gynaecology, Melaka
More informationBook Review: The Role of Education in the Rational use of Medicines
Article ID: WMC002475 ISSN 2046-1690 Book Review: The Role of Education in the Rational use of Medicines Corresponding Author: Dr. P Ravi Shankar, Professor, Medical Education, Pharmacology, KIST Medical
More informationInfiltrative Brain Mass Due To Progressive Alzheimer's Disease
Article ID: WMC00505 2046-1690 Infiltrative Brain Mass Due To Progressive Alzheimer's Disease Corresponding Author: Dr. Mark Lyons, Associate Professor, Mayo Clinic Arizona, 85054 - United States of America
More informationRadical Prostatectomy Does Not Increase the Risk of Inguinal Hernia
Article ID: WMC003763 ISSN 2046-1690 Radical Prostatectomy Does Not Increase the Risk of Inguinal Hernia Corresponding Author: Dr. Dan Spernat, Senior Lecturer University of Adelaide Urological Surgeon,
More informationCorresponding Author: Dr. Simon B Thompson, Associate Professor, Psychology Research Centre, Bournemouth University, BH12 5BB - United Kingdom
Article ID: 2046-1690 Thompson Digital Switch: Helping Stroke Patients to Help Themselves by Promoting Proprioception During Therapy. Brief Report and Podcast as a Teaching Aid for Professionals Corresponding
More informationCorresponding Author: Dr. Simon B Thompson, Associate Professor, Psychology Research Centre, Bournemouth University, BH12 5BB - United Kingdom
Article ID: 2046-1690 Thompson Digital Switch: Helping Stroke Patients to Help Themselves by Promoting Proprioception During Therapy. Brief Report and Podcast as a Teaching Aid for Professionals Corresponding
More informationA Case of Incisiform Supernumerary Tooth Along With a Impacted Supplemental Tooth In Anterior Maxillary Region
Article ID: WMC004147 ISSN 2046-1690 A Case of Incisiform Supernumerary Tooth Along With a Impacted Supplemental Tooth In Anterior Maxillary Region Corresponding Author: Dr. Keshav K Gautam, Service Senior
More informationDumbbell Ganglion Of The Foot: Case Report
Article ID: WMC001079 2046-1690 ISSN Dumbbell Ganglion Of The Foot: Case Report Author(s):Dr. S S Suresh, Dr. Hosam Zaki, Dr. Joyce Jose Corresponding Author: Dr. S S Suresh, Head of Department, Ibri Regional
More informationThe Role Of Varma Therapy In Cakana Vatam
Article ID: WMC002906 ISSN 2046-1690 The Role Of Varma Therapy In Cakana Vatam Corresponding Author: Dr. Shanmugasundaram Natarajan, Consultant Varmam Therapy, Siddha Regional Research Institute - India
More informationVariation of Superficial Palmar Arch: A Case Report
Article ID: WMC003387 ISSN 2046-1690 Variation of Superficial Palmar Arch: A Case Report Corresponding Author: Dr. Liju S Mathew, Demonstrator, Anatomy, Gulf Medical University, 4184 - United Arab Emirates
More informationThe Viability Of Human Embryos After Transport In A Dry Shipper Between Assisted Conception Laboratories
Article ID: WMC001104 2046-1690 The Viability Of Human Embryos After Transport In A Dry Shipper Between Assisted Conception Laboratories Corresponding Author: Ms. Clare Pinkus, Scientist, Hollywood Fertility
More informationComparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics
Research Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Dante M Durand,1, Phillip Harvey 1,2, Ricardo Cáceda 3 ABSTRACT Introduction: Clozapine
More informationEthics in Prehospital Emergency Medicine: An Ethical Dilemma in Patient Communication
Article ID: WMC004247 ISSN 2046-1690 Ethics in Prehospital Emergency Medicine: An Ethical Dilemma in Patient Communication Corresponding Author: Prof. Halvor Nordby, The University of Oslo, Faculty of
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationBipartite Patella: Two Cases Reports
Article ID: WMC003501 ISSN 2046-1690 Bipartite Patella: Two Cases Reports Corresponding Author: Dr. Fadwa Chami, Doctor, Hopital Denfants de Rabat - Morocco Submitting Author: Dr. Fadwa Chami, Doctor,
More informationArticle ID: WMC
Article ID: WMC001971 2046-1690 Evaluation of Visual Inspection with Acetic Acid (Via) & Visual Inspection with Lugol's Iodine (Vili) as a Screening Tool for Cervical Intraepithelial Neoplasia in Comparison
More informationSignet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report
Article ID: WMC00688 ISSN 2046-1690 Signet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report Author(s):Dr. Pallavi Bhuyan, Dr. Smita Mahapatra, Dr. Sujata Pujari, Dr. Jayasree Rath
More informationPilot Of Spontaneous Breathing Vs. Ventilated Model For Hemorrhage And Resuscitation In The Rabbit
Article ID: WMC001137 Pilot Of Spontaneous Breathing Vs. Ventilated Model For Hemorrhage And Resuscitation In The Rabbit Author(s):Dr. Jonathan S. Jahr, MD, Dr. Robert A. Gunther, PhD, Dr. Bernd Driessen,
More informationEndoscopic Detection and Removal of Recto-sigmoid Myomatous (Leiomyoma) Tumour
Article ID: ISSN 2046-1690 Endoscopic Detection and Removal of Recto-sigmoid Myomatous (Leiomyoma) Tumour Author(s):Mr. Sridhar Dharamavaram, Dr. Ritu Kamra, Dr. Anu Priya, Mr. Rajiva Ranjan Das Corresponding
More informationCompliance with Sleep Instructions After Total Hip Arthroplasty
Article ID: WMC002164 ISSN 2046-1690 Compliance with Sleep Instructions After Total Hip Arthroplasty Corresponding Author: Mr. Chetan S Modi, Registrar Trauma and Orthopaedic Surgery, Heart of England
More informationGorham Disease an Enigma
Article ID: WMC002898 ISSN 2046-1690 Gorham Disease an Enigma Corresponding Author: Dr. Prashant Kothari, Asso Professor, ODMR MCDRC, 442301 - India Submitting Author: Dr. Prashant Kothari, Asso Professor,
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationSCHIZOPHRENIA AN OVERVIEW
SCHIZOPHRENIA AN OVERVIEW Compiled by Campbell M Gold (2004) CMG Archives http://campbellmgold.com IMPORTANT The health information contained herein is not meant as a substitute for advice from your physician,
More informationVascular Risk Factors in Left Colon Anastomosis Leakage: A Computed Tomography Guided Study
Article ID: WMC003346 ISSN 2046-1690 Vascular Risk Factors in Left Colon Anastomosis Leakage: A Computed Tomography Guided Study Corresponding Author: Dr. Antonio Manenti, Associate Professor, Department
More informationSchizophrenia. Class Objectives. Can someone be psychotic without having schizophrenia? 12/7/2011. Other psychotic disorders and causes
Schizophrenia Other psychotic disorders and causes Class Objectives What are Delusional Disorders? What causes Schizophrenia? How can Schizophrenia be treated? Can someone be psychotic without having schizophrenia?
More informationIntroduction to Cofilin and its Regulation of Actin Dynamics
Article ID: ISSN 2046-1690 Introduction to Cofilin and its Regulation of Actin Dynamics Author(s):Mr. Kuen Yeow Chin Corresponding Author: Mr. Kuen Yeow Chin, MSc, Department of Cell and Developmental
More informationBipartite Patella: Two Cases Reports
Article ID: WMC003501 ISSN 2046-1690 Bipartite Patella: Two Cases Reports Corresponding Author: Dr. Fadwa Chami, Doctor, Hopital Denfants de Rabat - Morocco Submitting Author: Dr. Fadwa Chami, Doctor,
More informationScientific Misconduct
Article ID: WMC001719 ISSN 2046-1690 Scientific Misconduct Corresponding Author: Dr. Ulysses P Albuquerque, Professor, Universidade Federal Rural de Pernambuco - Brazil Submitting Author: Dr. Ulysses P
More informationKINDL Quality Of Life Questionnaire In Serbia: Referent Values For Healthy Children And Adolescents
Article ID: WC001342 2046-1690 KINDL Quality Of Life Questionnaire In Serbia: Referent Values For Healthy Children And Adolescents Corresponding Author: Dr. Dejan Stevanovic, Researcher/clinician, Psychiatry,
More informationSplenic Flexure Volvulus Presenting with Peritonitis: Case Report and Review of the Literature.
Article ID: WMC003974 ISSN 2046-1690 Splenic Flexure Volvulus Presenting with Peritonitis: Case Report and Review of the Literature. Corresponding Author: Dr. Gianrocco Manco, General Surgeon, Clinica
More informationArticle ID: WMC00596 ISSN
Article ID: WMC00596 ISSN 2046-1690 "Radio-Ulnar Synostosis Following Isolated Fracture Of Shaft Of Ulna And Its Treatment By Radical Excision And Interposition Of Tensor Fascia Lata Graft" Author(s):Dr.
More informationThe "Ultra Low" Duodenal Stump and its Difficult Management: An Old Technique Revisited
Article ID: WMC001998 2046-1690 The "Ultra Low" Duodenal Stump and its Difficult Management: An Old Technique Revisited Corresponding Author: Dr. Antonio Manenti, Associate Professor, Department Surgery
More informationScientific Misconduct
Article ID: WMC001617 2046-1690 Scientific Misconduct Corresponding Author: Dr. Ulysses P Albuquerque, Professor, Universidade Federal Rural de Pernambuco - Brazil Submitting Author: Dr. Ulysses P Albuquerque,
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationAdvancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study. Finding Clarity in the Midst of Uncertainty
Advancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study Finding Clarity in the Midst of Uncertainty Agenda Medication adherence in serious mental illness Consequences
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationBilateral Adrenal Myelolipoma: A Case Report and Review of Literature
Article ID: WMC004085 ISSN 2046-1690 Bilateral Adrenal Myelolipoma: A Case Report and Review of Literature Corresponding Author: Dr. Karthikeyan Selvaraju, Assistant Professor, Kasturba Medical College,
More informationCIRCULAR 58 OF 2018 : BENEFIT DEFINITION SUBMISSIONS FOR SCHIZOPHRENIA, BIPOLAR MOOD DISORDER AND MENTAL HEALTH EMERGENCIES
CIRCULAR Reference: Contact person: Mental Health PMB conditions Esnath Maramba Tel: 012 431 0507 Fax: 086 678 3598 E-mail: pmbprojects@medicalschemes.com Date: 13 December 2018 CIRCULAR 58 OF 2018 : BENEFIT
More informationUse of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
More informationThe Preperitoneal Inguinal Hernia Prosthetic Repair: Indications and Technical Notes
Article ID: WMC002622 2046-1690 The Preperitoneal Inguinal Hernia Prosthetic Repair: Indications and Technical Notes Corresponding Author: Dr. Antonio Manenti, Associate Professor, Department Surgery -
More informationTHERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA ABSTRACT Ph.D. Coordinator Professor Dragoș MARINESCU PhD Student: Mihai MUTICĂ Craiova 2016 TABLE OF CONTENTS
More informationIs Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective
More informationPrescribing for people with a personality disorder. POMH-UK QIP 12b
Prescribing for people with a personality disorder POMH-UK QIP 12b Personality disorder Personality disorders are a heterogeneous group of conditions which vary greatly in their severity Characterised
More informationPsoriasis Penis - A Two Case Report
Article ID: WMC003176 ISSN 2046-1690 Psoriasis Penis - A Two Case Report Corresponding Author: Dr. Ilko Bakardzhiev, MD, PhD, Medical College, Medical University of Varna, 9000 - Bulgaria Submitting Author:
More informationSchizophrenia. Can someone be psychotic without having schizophrenia? 11/30/2008. Name that Psychotic Disorder! Other psychotic disorders and causes
Schizophrenia Other psychotic disorders and causes Name that Psychotic Disorder! Chris has started spending large amounts of time guarding his home. They have bugged his phone and are sending cars past
More informationEffects of Smoking on Serum Lecithin: Cholesterol Acyltransferase Activity
Article ID: WMC004169 ISSN 2046-1690 Effects of Smoking on Serum Lecithin: Cholesterol Acyltransferase Activity Corresponding Author: Dr. K K Kshitiz, Assistant Professor, Biochemistry LHMC, G Block Patel
More informationDOWNLOAD OR READ : TREATMENT OF SCHIZOPHRENIA FAMILY ASSESSMENT AND INTERVENTION PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF SCHIZOPHRENIA FAMILY ASSESSMENT AND INTERVENTION PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of schizophrenia family assessment and intervention treatment of schizophrenia
More informationAdult Intussception : A Case Report
Article ID: ISSN 2046-1690 Adult Intussception : A Case Report Author(s):Dr. C Surendranath Singh, Prof. M.l. Prakash Corresponding Author: Dr. C Surendranath Singh, Senior Lecturer, Unit of Radiodiagnosis,
More informationResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prescribing Pattern of Antipsychotics In A Tertiary Care Hospital, Salem: A Retrospective Study. B Arul 1 *, E Manivannan 2, R Kothai
More informationSCHIZOPHRENIA SPECTRUM DISORDERS Psychiatry 2 Practical # 2
Psychiatrická klinika LFUK a UNB, Bratislava SCHIZOPHRENIA SPECTRUM DISORDERS Psychiatry 2 Practical # 2 Author: MUDr. Ľubomíra Izáková, PhD. Supervisor: doc. MUDr. Ján Pečeňák, CSc. Podporené grantom
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationAssessing cost-effectiveness of drug interventions for schizophrenia Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T
Assessing cost-effectiveness of drug interventions for schizophrenia Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T Record Status This is a critical abstract of an economic evaluation that meets the
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationUnderstanding of Oral Cancer Risk in Male Population of Guntur with Tobacco Habits?
Article ID: WMC003313 ISSN 2046-1690 Understanding of Oral Cancer Risk in Male Population of Guntur with Tobacco Habits? Corresponding Author: Dr. Madu G Prasad, Professor and HOD, Pedodontics and Preventive
More informationDexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery
Article ID: WMC002013 2046-1690 Dexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery Corresponding Author: Dr. Agreta Gashi, Anesthesiologist,
More informationPharmacological Managment of Treatment Resistant Schizophrenia. Jean-Marie Batail - France 21 st July 2015
Pharmacological Managment of Treatment Resistant Schizophrenia Jean-Marie Batail - France 21 st July 2015 Introduction A chronic and debilitating illness - Lifetime prevalence of around 0,7%. - Beginning
More informationTITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines
TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines DATE: 08 May 2014 CONTEXT AND POLICY ISSUES Electroconvulsive therapy (ECT) is a treatment that
More informationClozapine-induced concordant agranulocytosis
Ó 2001 Martin Dunitz Ltd International Journal of Psychiatry in Clinical Practice 2001 Volume 5 Pages 71 ± 73 71 Clozapine-induced concordant agranulocytosis in monozygotic twins J HORAÂ C Ï EK, J LIBIGER,
More informationStatistical Methods for Modeling HIV/AIDS in India
Article ID: WMC003336 ISSN 2046-1690 Statistical Methods for Modeling HIV/AIDS in India Corresponding Author: Dr. Brijesh Sathian, Assistant Professor & Managing and Chief Editor NJE, Community Medicine,
More informationChapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses
Chapter 17 Psychoses Drugs for Psychoses Delusions Hallucinations Illusions Paranoia Upper Saddle River, New Jersey 07458 All rights reserved. Classifications of Psychoses Acute episode Chronic episode
More informationPsychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com
Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Introduction Psychotic spectrum disorders include schizotypal personality disorder, delusional disorder, brief psychotic
More informationSalmonella Typhi Associated Hemophagocytic Lymphohistiocytosis in a Previously Healthy 23 Years Old Woman
Article ID: WMC001751 ISSN 2046-1690 Salmonella Typhi Associated Hemophagocytic Lymphohistiocytosis in a Previously Healthy 23 Years Old Woman Author(s):Dr. Dina Khalaf, Dr. Bassem Toema, Dr. Shaker Al-sadadi,
More informationIntroducing ValueOptions Clinical Care Alerts
Introducing ValueOptions Clinical Care Alerts January 2013 Agenda What are Clinical Care Alerts? How does it work? What are the benefits? Questions and Answers 2 The Issue of Poor Medication Adherence
More informationMental Health Current Articles Bulletin - April 2018
Library and Knowledge Services Mental Health Current Articles Bulletin - April 2018 How to Obtain an Article If you would like to request any articles included in this bulletin, or to be put onto the bulletin
More information4. General overview Definition
4. General overview 4.1. Definition Schizophrenia is a severe psychotic mental disorder characterized by significant disturbances of mental functioning. It has also been called early dementia, intrapsychic
More informationPrimitive Heart Undifferenciated Sarcoma: A case Report and Literature Review
Article ID: WMC003579 ISSN 2046-1690 Primitive Heart Undifferenciated Sarcoma: A case Report and Literature Review Corresponding Author: Dr. Hind El Yacoubi, Doctor, Medical Oncology Departement National
More informationAre Two Antipsychotics Better Than One?
Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office
More informationProfessor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with
More informationGoal: To recognize and differentiate different forms of psychopathology that involve disordered thinking and reasoning and distorted perception
Goal: To recognize and differentiate different forms of psychopathology that involve disordered thinking and reasoning and distorted perception Psychotic disorders, or psychoses, are among the most serious
More informationIEHP UM Subcommittee Approved Authorization Guidelines Electroconvulsive Therapy- ECT
Electroconvulsive Therapy- ECT Policy: IEHP considers ECT medically necessary for members with the following disorders: 1. Unipolar and bipolar depression. 2. Bipolar mania. 3. Psychotic disorders including
More informationBeyond clozapine: a review of the literature on clozapine resistance
Beyond clozapine: a review of the literature on clozapine resistance Jan Bogers j.bogers@ggzleiden.nl www.clozapinepluswerkgroep.nl Dutch Clozapine Collaboration Group Mental Health Services Rivierduinen
More informationEarly Stages of Psychosis. Learning Objectives
Early Stages of Psychosis Stephan Heckers, MD MSc Department of Psychiatry and Behavioral Sciences Vanderbilt University Learning Objectives Summarize the five domains of psychosis Describe how psychotic
More informationArticle ID: WMC00971 ISSN
Article ID: WMC00971 ISSN 2046-1690 Euthanasia Corresponding Author: Mr. Mohamed Najimudeen, Associate Professor, Obstetrics and Gynaecology, Melaka Manipal Medical College, Malaysia, Jalan Batu Hampar,
More informationTrichotillomania With Gastroduodenojejunal Trichobezoar
Article ID: WMC001367 2046-1690 Trichotillomania With Gastroduodenojejunal Trichobezoar Corresponding Author: Dr. Sanjay Somani, Consultant Gastroenterologist, Gastroenterology Department, Sahara Hospital,
More informationMethod. NeuRA Paliperidone August 2016
Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation
More informationSchizoaffective Disorder
Roseanna Parkhurst-Gatewood MSN FNP-BC, PMHNP-BC DSM-5 diagnostic criteria for schizoaffective disorder 3 A. An uninterrupted period of illness during which there is a major mood episode (major depressive
More informationCommunity Services - Eligibility
Community Services - Eligibility In order for DMH to reimburse care, the individual must meet both financial and clinical eligibility criteria. These criteria are described in detail in the DMH provider
More informationClozapine in community practice: a 3-year follow-up study in the Australian Capital Territory Drew L R, Hodgson D M, Griffiths K M
Clozapine in community practice: a 3-year follow-up study in the Australian Capital Territory Drew L R, Hodgson D M, Griffiths K M Record Status This is a critical abstract of an economic evaluation that
More informationSchizophrenia. Psychology 372 Physiological Psychology. Overview. Characterized by. Disorganized Thoughts Hallucinations Delusions Bizarre behaviors
Overview Schizophrenia Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Probably consists of more than one disorder Is the most devastating
More informationBorderline personality disorder: what role for medication?
Borderline personality disorder: what role for medication? Mike Crawford Imperial College London CNWL NHS Foundation Trust m.crawford@imperial.ac.uk Licensed medication for PD Jane, 34, moderately severe
More informationChapter 12 1/29/2018. Schizophrenia and Schizophrenia Spectrum Disorders. Epidemiology. Comorbidity. Lifetime prevalence of schizophrenia is 1%
Chapter 12 Schizophrenia and Schizophrenia Spectrum Disorders Epidemiology Lifetime prevalence of schizophrenia is 1% No difference related to 2 Comorbidity Substance abuse disorders Anxiety, depression,
More informationMinimising the Impact of Medication on Physical Health in Schizophrenia
Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,
More informationCoronary Angiographic Findings of Nepalese Patients with Critical Coronary Artery Disease: Which Vessels and How Severe?
Article ID: WMC002864 ISSN 2046-1690 Coronary Angiographic Findings of Nepalese Patients with Critical Coronary Artery Disease: Which Vessels and How Severe? Corresponding Author: Dr. Bharat Rawat, Managing
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationASAM Criteria, Third Edition Matrix for Matching Adult Severity and Level of Function with Type and Intensity of Service
1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 0 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 1 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 2 The patient
More informationRUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1
RUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1 Efficacy of Long Acting Injectable Antipsychotics in Early Onset Schizophrenia Linda Pietras RN-BC Mercyhurst University
More informationDexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery
Article ID: WMC002013 2046-1690 Dexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery Corresponding Author: Dr. Agreta Gashi, Anesthesiologist,
More informationSchizophrenia & the Antipsychotics
splitting of mind (cognition/emotion) from reality 1% of population globally shamans or mentally ill Several subtypes: paranoid / catatonic / disorganized / undifferentiated / residual positive ( exaggerated)
More informationMaking the Business Case for Long-Acting Injectables
Making the Business Case for Long-Acting Injectables David R. Swann, MA, LCAS, CCS, LPC, NCC Senior Healthcare Integration Consultant MTM Services Chief Clinical Officer Partners Behavioral Health Management
More informationPsychiatric Care. Course Goals
Course Goals Goals 1. Develop skills, knowledge & attitudes necessary to perform a psychiatric assessment consistent with level of training. 2. Develop skills to help patients identify current major concern(s),
More informationCHAPTER 3. Schizophrenia and Antipsychotic Treatment
CHAPTER 3 Schizophrenia and Antipsychotic Treatment What is it? It is a severe, chronic, disabling brain disease Considered to have biological origins but exact unknown 1% of population affected Schizophrenia
More informationMETHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC
PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM S.P. Lee 1 ; K. Lang 2 ; J. Jackel 2 ;
More information